Clinical Trial Update: iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a Phase 1/2 study of iExosomes in KRAS G12D-mutant metastatic pancreatic cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• iExosomes

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: KRAS NP_004976.2:p.G12D, Metastatic Pancreatic Adenocarcinoma | Phase 1, Phase 2 | Status: RECRUITING